Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/56—Materials from animals other than mammals
  • A61K35/63—Arthropods
  • A61K35/64—Insects, e.g. bees, wasps or fleas
  • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
  • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/74—Rubiaceae (Madder family)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

• the present invention relates generally to methods for treatment of sores and skin lesions and, more particularly, to methods for treating sores and lesions associated with Herpes Simplex Virus.
• Herpes Simplex Virus is a common cause of infections of the skin and mucus membranes. HSV is one of the most difficult viruses to control and has plagued civilization for thousands of years. HSV infection is typically manifested by painful, blister-like lesions or sores on the mouth or face (oral herpes) or in the genital area (genital herpes). While rarely fatal, herpes sores can be quite painful and unsightly and may cause embarrassment to the infected person.
• HSV-1 and HSV-2 are very similar. They can occur separately or can infect the same individual. HSV-1 is generally associated with oral herpes and HSV-2 is generally associated with genital herpes. It is now known, however, that HSV-2 can cause oral herpes and HSV-1 can cause genital herpes.
• HSV enters the body through the skin or mucus membranes following contact with an infected person.
• the virus penetrates vulnerable cells in the lower layers of the skin and attempts to replicate itself in the cell nuclei.
• HSV never causes symptoms to occur.
• HSV's replication process destroys the host cells, symptoms in the form of sores, ulcers, and fluid-filled blisters may appear.
• the sores from the primary infection eventually heal without scarring.
• the virus that caused the infection remains in the body and migrates through branches of nerve cells to clusters at the nerve cell ends called the ganglia.
• the virus persists in the ganglia in a latent state, during which viral replication does not occur. While the virus is latent, symptoms of the virus do not appear.
• Recurrent infections of HSV tend to be milder than primary infections and can be set off by a variety of factors, including illness and stress. For some persons infected with herpes virus, recurrent infections may be frequent. Approximately 20% to 40% of persons with HSV-1 experience recurrent outbreaks. For persons infected with HSV-2, the recurrence rate is up to 80%.
• the present invention comprises a pharmaceutical composition for topical application to treat sores, ulcers, lesions, or other disorders of the skin.
• the composition has been found to be effective for treatment of sores associated with Herpes Simplex Virus.
• the composition may also be useful for treatment of chicken pox, shingles, or other skin disorders resulting from viral infections.
• the active ingredients of the composition comprise a combination of a bee product and caffeine.
• the bee product may, for example, comprise honey, bee propolis, bee pollen, or royal jelly.
• Variations of the composition may also include tannin as an active ingredient.
• the composition may be in the form of a cream, ointment, or gell that is applied topically to the skin.
• the composition may also be used in other forms, such as a spray, shampoo, soap, lipstick, or adhesive bandage.
• the invention may also be useful as a health beverage.
• the present invention comprises compositions for topical application to the skin including as active ingredients a combination of a bee product and caffeine.
• the bee product may, for example, comprise honey, bee propolis, bee pollen, or royal jelly.
• compositions according to the present invention may be formed with active ingredients extracted from honey or other bee products, or with active ingredients synthesized to resemble the active ingredients in honey or bee products.
• the term bee product as used herein includes active ingredients extracted from bee products and active ingredients synthesized to resemble the active ingredients in bee products.
• Variations of the composition may also include a tannin as an active ingredient.
• a salve was prepared comprising a mixture of honey (preferably raw) and coffee grounds.
• the salve was prepared by combining approximately one tablespoon of coffee grounds with enough honey to hold the grounds together. It is estimated that the salve comprised approximately 15% by weight of honey.
• the salve was applied to sores of one patient caused by type I herpes simplex virus by spreading the salve over the sores and covering the sores with a bandage. Following application of the salve to the sores, the sores were reduced significantly in size within 3 to 4 hours and the sores were completely healed within 2 days. Prior to treatment with the anti-HSV composition, the patient experienced recurring infections once or twice a month. Following treatment, the patient has not had a single recurrence of the infection after more than five months.
• compositions according to the present invention may be made using micronized caffeine particles as described in U.S. Pat. No. 5,382,436, which is incorporated herein by reference. Further studies are needed in order to determine the amount of caffeine and bee product that is most efficacious. At present, the inventor believes that compositions containing greater than 1% by weight of caffeine would be effective.
• the composition may include, in addition to the active agents, a pharmaceutically acceptable excipient.
• Additives such as oils, thickening agents and emulsifiers may be used to form an ointment, cream, lotion or gel that is more suitable for topical application.
• natural oils include corn oil, almond oil, olive oil, coconut oil, caster oil, and lanolin oil.
• Synthetic oils, such as silicone oil may also be used.
• Possible thickening agents include natural waxes such as beeswax, paraffin waxes, and hydrocarbon polymers.
• U.S. Pat. No. 6,171,604 which is incorporated herein by reference, describes various honey-based preparations for topical application. Preparations described in this patent may be used with the present invention.
• the composition may be formed into an ointment, cream, salve, lotion, or gel that is applied topically to the skin.
• the composition may also be used in other forms, such as a spray, shampoo, soap, or lipstick.
• Another use of the present invention is in adhesive bandages having an absorbent pad that can be applied to the skin. Mixtures of caffeine and honey may also have use in health beverages that can be ingested. Beverages may be used to prevent outbreaks of HSV or other illnesses, or may be ingested to lessen the effect of an outbreak.
• CAPE suppresses the growth of cancerous cells and may, therefore, act as an anti-tumor agent.
• propolis has been shown to inhibit the growth of some viruses including herpes and influenza. Tannins are naturally occurring plant polyphenols which combine with protein and other polymers to form stable compounds. Some tannins are known to have antiseptic, antibiotic and antiviral properties. Tannins at relatively high concentrations can inhibit the activity of enzymes. Some tannins also show strong antitumor activity.
• Combined therapies have become increasingly popular in combating HSV and research has shown that certain drugs may enhance the effect of other drugs to produce not only an additive but also a synergistic effect.
• Combined therapies known to be effective for treatment of herpes include trifluorothymidine (TFT) with interferon-alpha, caffeine with interferon, and dimethyl sulfoxide (DMSO) with idoxuridine (IDU). It is suspected that the combination of a bee product and caffeine produces such a synergistic effect that inhibits replication of the virus more so than would treatment with either caffeine or bee product alone. Tannin may also play a role in retaining the active ingredients in honey and caffeine in the lower layers of the skin to prevent recurrence of HSV.
• composition is useful for the treatment of sores and lesions caused by herpes simplex virus, and may also be useful for the treatment of chicken pox, shingles or other viral infections.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Insects & Arthropods (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Molecular Biology (AREA)
• Virology (AREA)
• Botany (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Alternative & Traditional Medicine (AREA)
• Animal Husbandry (AREA)
• Zoology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (7)

Applications Claiming Priority (1)

Related Child Applications (1)

Publications (1)

Family

ID=33518088

Family Applications (2)

Family Applications After (1)

Country Status (6)

Cited By (17)

Families Citing this family (3)

Citations (15)

• 2003
  • 2003-06-23 US US10/602,404 patent/US20040258765A1/en not_active Abandoned
• 2004
  • 2004-06-22 AU AU2004251720A patent/AU2004251720B2/en not_active Ceased
  • 2004-06-22 EP EP04755805A patent/EP1643846A4/en not_active Ceased
  • 2004-06-22 CN CNA2004800242467A patent/CN1838885A/zh active Pending
  • 2004-06-22 CA CA2533591A patent/CA2533591C/en not_active Expired - Fee Related
  • 2004-06-22 WO PCT/US2004/019892 patent/WO2005000032A1/en active Search and Examination
• 2015
  • 2015-09-04 US US14/845,580 patent/US9387227B2/en not_active Expired - Lifetime

Patent Citations (15)

Also Published As

Similar Documents

Legal Events